| Literature DB >> 31416170 |
Junbo He1,2, Shuangshuang Huang1, Xiaotao Sun3, Lijuan Han1,2, Chao Chang1,2, Weinong Zhang4,5, Qixin Zhong6.
Abstract
To develop solid lipid nanoparticles (SLNs) with stable lipid matrix structures for the delivery of bioactive compounds, a new class of SLNs was studied using propylene glycol monopalmitate (PGMP) and glyceryl monostearate (GMS) mixtures and carvacrol as a model lipophilic antimicrobial. Stable SLNs were fabricated at PGMP:GMS mass ratios of 2:1 and 1:1, and the carvacrol loading was up to 30% of lipids with >98% encapsulation efficiency and absence of visual instability. Fluorescence spectra and release profiles indicated the carvacrol was successfully encapsulated and homogeneously distributed within the SLNs. SLNs fabricated with equal masses of PGMP and GMS had better stability of carvacrol during storage and higher sphericity than those with a ratio of 2:1 and were much more effective than free carvacrol against Escherichia coli O157:H7 and Staphylococcus aureus. These findings demonstrated the potential applications of the studied SLNs in delivering lipophilic bioactive compounds in food and other products.Entities:
Keywords: carvacrol; propylene glycol monopalmitate; solid lipid nanoparticles; synergistic antimicrobial activity
Year: 2019 PMID: 31416170 PMCID: PMC6723752 DOI: 10.3390/nano9081162
Source DB: PubMed Journal: Nanomaterials (Basel) ISSN: 2079-4991 Impact factor: 5.076
Scheme 1The microemulsion method for the preparation of carvacrol-loaded solid lipid nanoparticles (Car-SLNs).
Effects of mass ratio of PGMP and GMS on the Z-average mean diameter (Z-average), polydispersity index (PDI), zeta-potential, and visual stability of solid lipid nanoparticle dispersions.
| PGMP:GMS | Z-Average (nm) | PDI | Zeta-Potential (mV) | Visual Stability |
|---|---|---|---|---|
| 1:0 | 14.9 ± 0.4 | 0.133 ± 0.017 | 5.6 ± 0.9 | Precipitation after 3 days |
| 2:1 | 18.6 ± 0.2 | 0.178 ± 0.008 | −11.0 ± 0.1 | Stable for 1 month |
| 1:1 | 25.3 ± 0.7 | 0.296 ± 0.003 | −13.7 ± 0.8 | Stable for 1 month |
| 1:2 | ND 1 | ND | ND | Precipitation after 1 day |
| 0:1 | ND | ND | ND | Precipitation after 1 day |
1 ND: Not determined due to precipitation.
The Z-average mean diameter (Z-average), polydispersity index (PDI), zeta-potential, and encapsulation efficiency (EE%) values for the Car-SLNs dispersions 1.
| PGMP:GMS | Carvacrol Loading (% Mass of Lipids) | Z-Average (nm) | PDI | Zeta-Potential (mV) | EE (%) | |||
|---|---|---|---|---|---|---|---|---|
| 0 Day | 30 Days | 0 Day | 30 Days | 0 Day | 30 Days | 0 Days | ||
| 2:1 | 0 | 18.6 ± 0.2 d | 32.9 ± 0.5 d | 0.178 ± 0.008 a | 0.292 ± 0.027 b | −11.0 ± 0.1 ab | −14.1 ± 1.6 c | |
| 20 | 39.8 ± 0.6 c | 149.4 ± 1.8 c | 0.184 ± 0.010 a | 0.221 ± 0.018 c | −9.73 ± 0.1 b | −18.5 ± 0.7 b | 98.0 ± 0.1 c | |
| 30 | 68.9 ± 0.1 b | 159.8 ± 2.5 b | 0.182 ± 0.012 a | 0.313 ± 0.002 a,b | −12.6 ± 1.7 a | −21.2 ± 1.6 a,b | 98.3 ± 0.1 a | |
| 40 | 95.4 ± 0.7 a | 165.8 ± 3.4 a | 0.182 ± 0.008 a | 0.355 ± 0.051 a | −11. 9± 1.4 a,b | −23.2 ± 2.9 a | 98.2 ± 0.2 a,b | |
| 1:1 | 0 | 25.3 ± 0.7 d | 55.1 ± 0.2 d | 0.296 ± 0.003 a | 0.278 ± 0.003 a | −13.7 ± 0.8 b | −15.3 ± 1.3 c | |
| 20 | 56.1 ± 0.3 c | 98.7 ± 0.9 c | 0.211 ± 0.010 c | 0.198 ± 0.002 c | −17.1 ± 0.6 a | −17.4 ± 1.1 b | 99.2 ± 0.1 b | |
| 30 | 89.3 ± 1.2 b | 155.2 ± 2.7 b | 0.224 ± 0.008 c | 0.233 ± 0.004 b | −17.9 ± 1.4 a | −18.6 ± 1.2 a,b | 99.4 ± 0.1 a | |
| 40 | 115.8 ± 0.8 a | 193.5 ± 2.5 a | 0.239 ± 0.005 b | 0.228 ± 0.016 b | −16.6 ± 0.6 a | −19.9 ± 0.5 a | 98.1 ± 0.1 c | |
1 Data not sharing the same superscript letter in the same column are significantly different (p < 0.05).
Figure 1Intensity size distributions of SLNs prepared with a PGMP:GMS mass ratio of 2:1 (a) or 1:1 (b) and a carvacrol loading at 30% mass of lipids, before (black column) and after (red column) 30-day storage at 25 °C.
Chemical stability of free carvacrol and carvacrol loaded in SLNs.
| PGMP:GMS | Carvacrol Loading (% Mass of Lipids) | Residual Carvacrol (%) 2 | |
|---|---|---|---|
| 7 day | 30 days | ||
| 2:1 | 20 | 91.6 ± 3.9 b | 90.3 ± 3.1 ab |
| 30 | 92.7 ± 2.1 ab | 86.5 ± 2.2 bc | |
| 40 | 91.6 ± 3.0 b | 83.7 ± 3.9 cd | |
| 1:1 | 20 | 95.7 ± 3.1 a | 92.0 ± 2.8 a |
| 30 | 95.9 ± 0.7 a | 92.6 ± 1.3 a | |
| 40 | 95.0 ± 2.0 a | 87.1 ± 1.2 bc | |
| Free carvacrol 1 | 84.1 ± 1.1 c | 80.0 ± 1.8 d | |
1 Free carvacrol was prepared in ethanol at the same concentration as SLNs with a carvacrol loading at 30% mass of lipids. 2 Data not sharing the same superscript letter in the same column are significantly different (p < 0.05).
Figure 2Fluorescence spectra of Car-SLNs with a carvacrol loading at 30% mass of lipids and a PGMP:GMS mass ratio of 2:1 or 1:1 and the corresponding bare SLNs without carvacrol, and carvacrol pre-dissolved in ethanol and water.
Figure 3Release profiles of carvacrol from SLNs with a carvacrol loading at 30% mass of lipids and a PGMP:GMS mass ratio of 2:1 (b) or 1:1 (a), with comparison to free carvacrol dissolved in ethanol (c). The inset figure shows release kinetics in the first 5 h. The released carvacrol was detected in the release medium outside the dialysis bag. Error bars are standard derivations (n = 3).
Figure 4TEM analysis of Car-SLNs prepared with a carvacrol loading at 30% mass of lipids and a PGMP:GMS mass ratio of 2:1 (a) or 1:1 (b). The particles shown in insert images were pointed by red arrows.
Antimicrobial activities of Car-SLNs with a carvacrol loading at 30% mass of lipids, free carvacrol, and two bare SLNs.
| PGMP:GMS | MIC (mg/mL) | MBC (mg/mL) | ||
|---|---|---|---|---|
|
|
| |||
| 2:1, bare SLNs | 0.300 | 0.300 | 0.350 | 0.350 |
| 2:1, Car-SLNs | 0.150 | 0.100 | 0.200 | 0.125 |
| 1:1, bare SLNs | 0.250 | 0.250 | 0.300 | 0.300 |
| 1:1, Car-SLNs | 0.125 | 0.100 | 0.125 | 0.100 |
| Free carvacrol | 0.250 | 0.125 | 0.250 | 0.125 |